Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company focused on anti-infective agents, announced that CEO Ted Schroeder will present a company overview and business update at the Jefferies Virtual Healthcare Conference on June 3, at 2:30 p.m. ET. The presentation can be accessed via the 'Investors' section of Nabriva's website.
Nabriva is known for its FDA-approved XENLETA, the first pleuromutilin antibiotic for community-acquired bacterial pneumonia, and is developing CONTEPO for complicated urinary tract infections. It has an agreement with Merck to market SIVEXTRO.
Details
News Market Reaction – NBRV
The recorded move for NBRV in the trading session of this news was -1.32%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 2:30 p.m. ET.
The presentation may be accessed by visiting the "Investors" section of the Company's website under the "Events and Presentations" tab at www.nabriva.com.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.
CONTACTS:
For Investors
Kim Anderson
Nabriva Therapeutics plc
IR@Nabriva.com
For Media
Andrea Greif
Ogilvy
andrea.greif@ogilvy.com
914-772-3027
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.